

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6591475

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	HERRIOT TABUTEAU	11/24/2020
RECEIVING PARTY DATA		
Name:	ANTECIP BIOVENTURES II LLC	
Street Address:	630 FIFTH AVENUE, SUITE 2000	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10111	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17196338
CORRESPONDENCE DATA		
Fax Number:	(435)252-1361	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	949-202-1900	
Email:	Docket@mabr.com	
Correspondent Name:	BRENT A. JOHNSON	
Address Line 1:	MASCHOFF BRENNAN	
Address Line 2:	100 SPECTRUM CENTER DRIVE, SUITE 1200	
Address Line 4:	IRVINE, CALIFORNIA 92618	
ATTORNEY DOCKET NUMBER:	A3226.10002US126	
NAME OF SUBMITTER:	MARIA NADAL	
SIGNATURE:	/Maria Nadal/	
DATE SIGNED:	03/09/2021	
Total Attachments: 7		
source=A3226.10002US126 - EXECUTED ASSIGNMENT PARENT#page1.tif		
source=A3226.10002US126 - EXECUTED ASSIGNMENT PARENT#page2.tif		
source=A3226.10002US126 - EXECUTED ASSIGNMENT PARENT#page3.tif		
source=A3226.10002US126 - EXECUTED ASSIGNMENT PARENT#page4.tif		
source=A3226.10002US126 - EXECUTED ASSIGNMENT PARENT#page5.tif		

source=A3226.10002US126 - EXECUTED ASSIGNMENT PARENT#page6.tif

source=A3226.10002US126 - EXECUTED ASSIGNMENT PARENT#page7.tif

ASSIGNMENT

THIS ASSIGNMENT is made by **Herriot Tabuteau** (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNOR") to **Antecip Bioventures II LLC**, a legal entity having its principal place of business at 630 Fifth Avenue, Suite 2000, New York, New York 10111 (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNEE").

WHEREAS, ASSIGNOR has invented and owns rights in, to and under new and useful inventions for which an application(s) for or Letters Patent has been filed as indicated on **Exhibit A** (hereafter "Inventions");

WHEREAS, ASSIGNOR believes himself to be the original and true inventor of the Inventions;

WHEREAS, ASSIGNEE desires to acquire the Inventions and improvements thereto;

AND WHEREAS, ASSIGNOR and ASSIGNEE desire to have a recordable instrument assigning ASSIGNEE as owners of the entire right, title and interest in, to, and under the Inventions and improvements thereto owned by ASSIGNOR;

NOW THEREFORE, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign, transfer, convey, endorse, and hereby set over unto ASSIGNEE the full and exclusive right, title and interest in, to and under the Inventions to be held and enjoyed by ASSIGNEE, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made including the full and exclusive right, title and interest in, to and under 1) any patent application, or any other legal instrument equivalent thereof, including, without limitation, continuation, division, continuation-in-part, substitute, reexamination, renewal, inventor's certificate, and utility model, which has been or may be submitted therefor and thereon anywhere in the World, such term defined herein as including the United States of America, its territorial possessions, and any and all foreign countries under national laws or under the provisions of the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or any other international treaty equivalent thereof; 2) any Letters Patent, or any other legal instrument equivalent thereof, which has been or may be granted therefor and thereon, in the World, for the full term or terms for which the same may be granted; 3) any reissue, extension, or any other legal instrument equivalent thereof, on any patent application or Letters Patent which has been or may be granted therefor and thereon in the World; and 4) any right to claim priority to a filing date, or any other legal equivalent thereof, which has been or may be claimed by any patent application or Letters Patent therefor and thereon in the World.

ASSIGNOR hereby covenants and agrees to perform any lawful action when deemed essential by and to ASSIGNEE's full enjoyment, protection, enforcement and title in, to and under the Inventions and rights hereby transferred, including, but not limited to, promptly communicating and providing any and all known and accessible facts, data or any other pertinent information; promptly executing and delivering any and all papers, documents, forms, declarations, oaths, affidavits or any other legal instrument; promptly assisting and participating in any and all depositions, hearings, proceedings, trials, appeals, or any other legal procedure; promptly testifying under oath in any and all interference, post grant review, litigation or any other

administrative or judicial proceeding; and promptly completing any and all actions necessary or desirable to carry out any and all purposes thereof, relating to any and all proceedings in connection with the submission, procurement, issuance, maintenance, enforcement or defense of the inventions and rights hereby transferred.

The undersigned hereby grant to the firm of Maschoff Brennan, 100 Spectrum Center Drive, Suite 1200, Irvine CA 92618, the power to insert in this Assignment any further information, such as the application number, which may be necessary or desirable for identification of the Inventions and/or for recordation of this Assignment.

A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.

IN TESTIMONY WHEREOF, I hereunder set my hand this 24 day of Nov., 2020.

ASSIGNOR

Herriot Tabuteau

Signature

State of New York)

County of New York)

ss.:

On this 24 day of Nov, 2020, before me, Neil Schneider, personally appeared **Herriot Tabuteau**, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.

Neil Schneider
Notary Public

NEIL SCHNEIDER
NOTARY PUBLIC-STATE OF NEW YORK
No. 01SC6065135
Qualified in New York County
My Commission Expires 10-09-2021

A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.

ACKNOWLEDGED AND CONFIRMED, I hereunder set my hand this 24 day of Nov., 2020, as a duly authorized representative of ASSIGNEE.

ASSIGNEE

Antecip Bioventures II LLC


Name: **Herriot Tabuteau, MD**
Title: **Managing Member**

State of New York)

County of New York)

SS.:

On this 24 day of Nov, 2020, before me, Neil Schneider, personally appeared **Herriot Tabuteau** who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.


Notary Public

NEIL SCHNEIDER
NOTARY PUBLIC-STATE OF NEW YORK
No. 01SC6065135
Qualified in New York County
My Commission Expires 10-09-2021

EXHIBIT A

<u>Title</u>	<u>Serial No.</u>	<u>Filing Date</u>
BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION	16/817,119	03/12/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/821,330	03/17/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/821,462	03/17/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/822,564	03/18/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/822,697	03/18/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/823,724	03/19/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/823,807	03/19/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/825,195	03/20/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/825,228	03/20/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/826,580	03/23/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/826,598	03/23/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/828,237	03/23/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	63/002,132	03/30/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/838,829	04/02/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/852,939	04/20/2020

Title	Serial No.	Filing Date
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/853,062	04/20/2020
BUPROPION AND DEXTROMETHORPHAN FOR TREATING AGITATION IN ALZHEIMER'S DISEASE	63/016,178	04/27/2020
BUPROPION AND DEXTROMETHORPHAN FOR TREATING AGITATION IN ALZHEIMER'S DISEASE	63/016,208	04/27/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	63/032,517	05/29/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	63/032,567	05/30/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/894,713	06/05/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/926,458	07/10/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/983,873	08/03/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/002,017	08/25/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/003,777	08/26/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	63/077,606	09/12/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/020,393	09/14/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	63/078,190	09/14/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/022,629	09/16/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/022,781	09/16/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/024,145	09/17/2020

Title	Serial No.	Filing Date
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/025,849	09/18/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/027,608	09/21/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/030,129	09/23/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/039,551	09/30/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/061,047	10/01/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/063,364	10/05/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/066,310	10/08/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/068,309	10/12/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/070,706	10/14/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/071,925	10/15/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/075,189	10/20/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/087,890	11/03/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	63/109,326	11/03/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/092,968	11/09/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/095,256	11/11/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/097,486	11/13/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/099,226	11/16/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/950,838	11/17/2020

<u>Title</u>	<u>Serial No.</u>	<u>Filing Date</u>
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	16/952,759	11/19/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/100,456	11/20/2020
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	17/103,819	11/24/2020